Fibroblast growth factor and hepatocyte growth factor in adolescents with juvenile idiopathic arthritis treated with methotrexate

Authors

DOI:

https://doi.org/10.15587/2519-4798.2020.213126

Keywords:

juvenile idiopathic arthritis, methotrexate, fibroblast growth factor, hepatocyte growth factor, adiponectin, APRI index, FIB-4 Score, liver ultrasound, adolescents, liver

Abstract

Methotrexate (MTX) is a cornerstone of therapy worldwide for juvenile idiopathic arthritis (JIA). Despite the fact that fibrosis molecular mechanisms as well as MTX elimination and fibrosis indexes were studied a lot there is still not enough information for adolescence.

The aim was to study dynamics of molecular-cellular mechanisms activation of fibrotic processes development in the liver in adolescents with juvenile idiopathic arthritis treated with methotrexate by determining the content of fibroblast growth factor and hepatocyte growth factor.

Materials and methods: A total of 68 children with juvenile idiopathic arthritis, were enrolled in the study. 25 boys (36.8 %) and 43 girls (63.2 %) were examined. Children were divided into four groups in accordance with cumulative dose (CD) of methotrexate. The following data were analyzed: liver function tests (aspartate aminotransferase (AST) (U/L), alanylaminotransferase (ALT) (U/L)), lactate dehydrogenase (LDH) (U/L), adiponectin (μg / ml), BFGF (pg / ml), HGF (pg / ml), liver fibrosis indexes APRI and FIB-4 Score.

Results. Positive effect of JIA treatment with MTX on the liver is noted. When CD MTX reaches 1 and3 grams, liver state studying is needed. When the CD MTX of1 gram is reached, regulatory mechanisms are involved that provoke liver regeneration. When the CD MTX reaches3 grams, the liver condition may deteriorate, which in the future can lead to irreversible processes of liver fibrosis.

Conclusions: Thus, it is important to control possible liver disorders in adolescence treated with MTX. Monitoring the processes of liver fibrosis is appropriate at all stages of JIA treatment, but it is most advisable when the MTX cumulative dose is reaching 1 and3 grams

Author Biography

Olga Pavlova, Kharkiv Medical Academy of Postgraduate Education Amosova str., 58, Kharkiv, Ukraine, 61176

Postgraduate Student

Department of Adolescent Medicine

References

  1. Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M. et. al. (2017). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 76 (6), 960–977. doi: http://doi.org/10.1136/annrheumdis-2016-210715
  2. Desmoulin, S. K., Hou, Z., Gangjee, A., Matherly, L. H. (2012). The human proton-coupled folate transporter. Cancer Biology & Therapy, 13 (14), 1355–1373. doi: http://doi.org/10.4161/cbt.22020
  3. Seideman, P., Beck, O., Eksborg, S., Wennberg, M. (1993). The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. British Journal of Clinical Pharmacology, 35 (4), 409–412. doi: http://doi.org/10.1111/j.1365-2125.1993.tb04158.x
  4. Conway, R., Carey, J. J. (2017). Risk of liver disease in methotrexate treated patients. World Journal of Hepatology, 9 (26), 1092–1100. doi: http://doi.org/10.4254/wjh.v9.i26.1092
  5. Chan, E. S. L., Montesinos, M. C., Fernandez, P., Desai, A., Delano, D. L., Yee, H. et. al. (2006). Adenosine A2Areceptors play a role in the pathogenesis of hepatic cirrhosis. British Journal of Pharmacology, 148 (8), 1144–1155. doi: http://doi.org/10.1038/sj.bjp.0706812
  6. Che, J., Chan, E. S. L., Cronstein, B. N. (2007). Adenosine A2A Receptor Occupancy Stimulates Collagen Expression by Hepatic Stellate Cells via Pathways Involving Protein Kinase A, Src, and Extracellular Signal-Regulated Kinases 1/2 Signaling Cascade or p38 Mitogen-Activated Protein Kinase Signaling Pathway. Molecular Pharmacology, 72 (6), 1626–1636. doi: http://doi.org/10.1124/mol.107.038760
  7. Aithal, G. P. (2011). Hepatotoxicity related to antirheumatic drugs. Nature Reviews Rheumatology, 7 (3), 139–150. doi: http://doi.org/10.1038/nrrheum.2010.214
  8. Ortega-Alonso, A., Andrade, R. J. (2018). Chronic liver injury induced by drugs and toxins. Journal of Digestive Diseases, 19 (9), 514–521. doi: http://doi.org/10.1111/1751-2980.12612
  9. Vardi, N., Parlakpinar, H., Cetin, A., Erdogan, A., Cetin Ozturk, I. (2010). Protective Effect of β-Carotene on Methotrexate–Induced Oxidative Liver Damage. Toxicologic Pathology, 38 (4), 592–597. doi: http://doi.org/10.1177/0192623310367806
  10. Nunes, Q. M., Li, Y., Sun, C., Kinnunen, T. K., Fernig, D. G. (2016). Fibroblast growth factors as tissue repair and regeneration therapeutics. PeerJ, 4, e1535. doi: http://doi.org/10.7717/peerj.1535
  11. Maddaluno, L., Urwyler, C., Werner, S. (2017). Fibroblast growth factors: key players in regeneration and tissue repair. Development, 144 (22), 4047–4060. doi: http://doi.org/10.1242/dev.152587
  12. Kang, J., Hu, J., Karra, R., Dickson, A. L., Tornini, V. A., Nachtrab, G. et. al. (2016). Modulation of tissue repair by regeneration enhancer elements. Nature, 532 (7598), 201–206. doi: http://doi.org/10.1038/nature17644
  13. Kan, M., Huang, J. S., Mansson, P. E., Yasumitsu, H., Carr, B., McKeehan, W. L. (1989). Heparin-binding growth factor type 1 (acidic fibroblast growth factor): a potential biphasic autocrine and paracrine regulator of hepatocyte regeneration. Proceedings of the National Academy of Sciences, 86 (19), 7432–7436. doi: http://doi.org/10.1073/pnas.86.19.7432
  14. Aw, M. M., Mitry, R. R., Hughes, R. D., Dhawan, A. (2007). Serum Hepatocyte Growth Factor and Vascular Endothelial Growth Factor in Children with Acute Liver Failure. Journal of Pediatric Gastroenterology and Nutrition, 44 (2), 224–227. doi: http://doi.org/10.1097/mpg.0b013e31802c686b
  15. Michalopoulos, G. K. (2017). Hepatostat: Liver regeneration and normal liver tissue maintenance. Hepatology, 65 (4), 1384–1392. doi: http://doi.org/10.1002/hep.28988
  16. Zhang, X., Olsavszky, V., Yin, Y., Wang, B., Engleitner, T., Öllinger, R. et. al. (2020). Angiocrine Hepatocyte Growth Factor Signaling Controls Physiological Organ and Body Size and Dynamic Hepatocyte Proliferation to Prevent Liver Damage during Regeneration. The American Journal of Pathology, 190 (2), 358–371. doi: http://doi.org/10.1016/j.ajpath.2019.10.009
  17. Strashok, L. A., Pavlova, O. S. (2020). Determination of liver damage indices APRI and FIB-4 score in adolescents with juvenile idiopathic arthritis. Child`s health, 15 (3), 154–159. doi: http://doi.org/10.22141/2224-0551.15.3.2020.204549

Downloads

Published

2020-09-30

How to Cite

Pavlova, O. (2020). Fibroblast growth factor and hepatocyte growth factor in adolescents with juvenile idiopathic arthritis treated with methotrexate. ScienceRise: Medical Science, (5 (38), 53–57. https://doi.org/10.15587/2519-4798.2020.213126

Issue

No. 5 (38) (2020)

Section

Medical Science

License

Copyright (c) 2020 Olga Pavlova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.